UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly one in 2,000 ...

Blocking the brain protein EPAC2 reverses sensory hypersensitivity, social deficits, and seizures in Fragile X syndrome.

UCLA Health researchers have identified a potential drug target for treating fragile X syndrome (FXS), the most common genetic cause of intellectual disability and autism that affects roughly one in 2 ...

Salk Institute scientists find correcting dysregulations in star-shaped brain cells called astrocytes improves some fragile X syndrome symptoms, making the cells potential future therapeutic targets ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

Scientists have created a new therapeutic approach for testing fragile X syndrome, which is the most common genetic cause of autism spectrum disorder (ASD). This method aims to alter a type of neural ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's ...

UC Davis MIND Institute researchers Randi and Paul Hagerman are calling for increased awareness and screening for fragile X-associated conditions. In a new paper published in the New England Journal ...

A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.